clear
pandem
global
health
crisi
potenti
kill
million
peopl
particularli
elderli
peopl
comorbid
hypertens
smoke
lung
diseas
present
know
peopl
ms
increas
risk
acqur
develop
sever
individu
ms
uniqu
requir
treat
immunosuppress
therapi
discuss
epidem
renal
transplant
team
inform
us
present
take
specif
action
level
immunosuppress
transplant
patient
epidem
basic
measur
recommend
name
improv
hand
home
hygien
avoid
highrisk
travel
unnecessari
contact
selfisol
necessari
reduc
contact
hospit
medic
institut
much
possibl
like
sourc
busi
usual
necessarili
halt
transplant
programm
argument
transplant
kidney
transplant
organ
preciou
protect
relev
immunosuppress
drug
would
attitud
brain
spinal
cord
patient
activ
multipl
sclerosi
could
argu
solidorgan
transplant
patient
significantli
immunocompromis
pwm
diseas
modifi
treatment
dmt
transplant
patient
tripl
immunotherapi
compar
pwm
monotherapi
even
level
immunosuppress
gener
low
henc
mortalitymorbid
risk
individu
dmt
infect
may
actual
quit
moder
low
anoth
hypothesi
consid
moder
immunosuppress
may
prevent
sever
complic
associ
infect
sever
pulmonari
complic
infect
consist
ard
acut
respiratori
distress
syndrom
caus
overexuber
immun
respons
viru
ramanathan
et
al
result
sever
exploratori
trial
current
undertaken
china
elsewher
use
immunosuppress
tri
dampen
immun
respons
viru
interestingli
fingolimod
modul
licens
ms
test
treatment
associ
ard
continu
next
page
g
giovannoni
et
al
multipl
sclerosi
relat
disord
clinicaltrialsgov
identifi
interferon
beta
also
triall
base
antivir
properti
clinicaltrialsgov
identifi
virolog
take
account
caus
new
human
pathogen
like
recent
cross
speci
andersen
et
al
eventu
becom
endem
henc
pose
season
risk
patient
immunosuppress
therapi
small
rna
viru
low
fidel
like
mutat
rapidli
make
oneoff
vaccin
partial
solut
vaccin
take
time
develop
test
introduc
popul
level
delay
treatment
deescal
therapi
switch
immunomodulatori
dmt
interferonbeta
glatiram
acet
teriflunomid
interrupt
dose
dmt
wait
vaccin
delay
adequ
treatment
ms
especi
may
take
month
develop
vaccin
therefor
need
pragmat
respons
manag
potenti
threat
individu
ms
patient
activ
ms
need
treat
base
clinic
evid
hand
henc
may
need
treat
higher
efficaci
dmt
implement
conjunct
appropri
behaviour
modif
reduc
ideal
prevent
exposur
viru
essenti
consid
potenti
risk
morbid
possibl
mortal
ms
patient
may
infect
develop
individu
risk
profil
multifactori
dmt
consequ
immun
respons
one
factor
aspect
consid
assess
respiratori
viral
infect
includ
smoke
practic
increas
cigarett
smoke
increas
risk
ambulatori
statu
less
mobil
increas
risk
especi
patient
wheelchair
age
increas
age
increas
risk
weight
increas
weight
impact
ambul
respiratori
function
underli
respiratori
ill
asthma
copd
also
frequenc
necessari
attend
hospit
healthcar
facil
laboratori
mri
test
also
infus
may
place
patient
higher
risk
exposur
context
factor
health
care
profession
weigh
potenti
risk
exposur
manag
dmt
accordingli
visit
ms
care
prefer
done
telemedicin
phone
potenti
hazard
pose
dmt
differ
rather
impos
blanket
rule
decis
regard
treatment
individualis
see
tabl
discuss
patient
patient
ms
treat
control
may
import
potenti
danger
expos
acquir
sever
infect
tabl
attempt
defin
risk
associ
differ
class
dmt
event
patient
acquir
infect
assum
antivir
respons
driven
mainli
tcell
particular
cytotox
tlymphocyt
naturalkil
cell
less
least
initi
bcell
allow
one
construct
hierarchi
immunosuppress
dmt
highest
risk
immun
reconstitut
therapi
deplet
phase
treatment
ie
haematopoiet
stem
cell
transplant
hsct
alemtuzumab
lemtrada
mitoxantron
novantron
cladribin
mavenclad
immun
reconstitut
total
lymphocyt
count
return
normal
near
normal
risk
sever
viral
infect
probabl
higher
expect
background
popul
would
associ
age
comorbid
pleas
note
immun
reconstitut
take
month
year
patient
last
cours
treatment
previou
month
may
still
immunocompromis
total
lymphocyt
count
less
l
mm
associ
increas
risk
infect
infectionrel
mortal
warni
et
al
risk
increas
progress
lower
absolut
lymphocyt
count
particularli
lymphocyt
count
drop
risk
warni
et
al
rough
guid
pwm
lymphocyt
count
grade
abl
deal
viral
infect
reason
well
provid
comorbid
rel
young
risk
refer
acquir
infect
immunodeplet
phase
post
immun
reconstitut
risk
low
g
giovannoni
et
al
multipl
sclerosi
relat
disord
immun
reconstitut
therapi
cladribin
mavenclad
class
intermedi
risk
rel
poor
tcell
deplet
agent
stuve
et
al
tcell
deplet
postcladribin
averag
popul
sensit
popul
phase
clariti
studi
viral
infect
uncommon
postcladribin
apart
herp
zoster
infect
frequent
cladribinetr
subject
compar
placebo
cook
et
al
viral
infect
occur
postcladribin
tend
mild
moder
sever
similarli
therapi
ocrelizumab
minor
impact
tcell
count
associ
sever
viral
infect
mayer
et
al
phase
relapsingremit
primari
progress
trial
infect
slightli
frequent
ocrelizumab
compar
compar
arm
placebo
montalban
et
al
infect
mild
moder
sever
infect
bacteri
natur
pneumonia
urinari
tract
infect
cellul
therefor
feel
cladribin
therapi
rel
safe
use
pandem
base
profil
defin
phase
trial
modul
fingolimod
siponimod
ozanimod
ponesimod
work
reduc
egress
lymphocyt
secondari
lymphoid
organ
circul
stepanovska
huwil
actual
degre
lymphopaenia
associ
efficaci
risk
infect
franci
et
al
overal
infecti
complic
rel
low
modul
opportunist
infect
emerg
time
epstein
et
al
luna
et
al
importantli
vast
major
patient
modul
problem
deal
commun
acquir
viral
infect
patient
fingolimod
expos
acquir
exot
viral
infect
dengu
fever
seem
deal
without
complic
fragoso
et
al
patient
modul
rel
low
risk
complic
infect
may
safe
continu
treatment
epidem
fingolimod
howev
blunt
vaccin
respons
kappo
et
al
indic
prime
effector
arm
immun
system
affect
whether
impact
outcom
present
unknown
although
neurologist
consid
natalizumab
rel
safe
small
increas
risk
upper
respiratori
tract
infect
medic
kapoor
et
al
polman
et
al
rudick
et
al
theoret
reason
may
reduc
traffick
lymphocyt
lung
mucosa
woodsid
vanderslic
clear
natalizumab
block
immun
surveil
cn
henc
person
natalizumab
develop
enceph
could
danger
major
complic
infect
latter
analog
pml
also
viral
enceph
similar
herpessimplex
varicella
zoster
enceph
result
natalizumab
exposur
fine
et
al
coronavirus
potenti
neurotrop
one
onlin
case
report
old
chines
man
develop
enceph
develop
decreas
level
conscious
normal
ct
scan
brain
spinal
fluid
analysi
reveal
subsequ
made
recoveri
discharg
xinhua
also
clear
evid
larg
chines
cohort
anosmia
may
earli
sign
infect
suggest
involv
neuraxi
anoth
human
coronaviru
gener
associ
mild
upper
respiratori
tract
infect
shown
neuroinvas
properti
studi
mice
shown
infect
neuron
caus
enceph
caus
persist
infect
human
neuralcel
line
arbour
et
al
case
report
identifi
rna
cerebrospin
fluid
brain
children
acut
dissemin
encephalomyel
yeh
et
al
acut
encephalomyel
morfopoul
et
al
coronavirus
mutat
rapidli
henc
may
produc
neurotrop
strain
quit
quickli
latter
potenti
issu
context
natalizumab
creat
immun
privileg
site
may
allow
select
neurotrop
mutant
anoth
aspect
need
consid
happen
gut
infect
gastrointestin
tract
peopl
develop
diarrhoea
guan
et
al
shed
stool
holshu
et
al
natalizumab
also
reduc
lymphocyt
traffick
gut
licens
treatment
crohn
diseas
ghosh
et
al
patient
natalizumab
dmt
increas
viral
replic
gut
shed
stool
patient
natalizumab
dmt
infect
viru
becom
superspread
despit
question
current
scienc
indic
patient
natalizumab
abl
deal
novel
viral
infect
dengu
fragoso
et
al
reassuringli
five
patient
natalizumab
infect
dengu
viru
clear
viru
without
complic
similar
fingolimod
fragoso
et
al
clearli
decis
start
dmt
pandem
need
taken
care
depend
state
pandem
particular
countri
concern
specif
area
patient
live
receiv
therapi
exampl
aggress
public
health
step
contain
spread
viru
local
may
make
rel
safe
patient
start
immunosuppress
therapi
concern
pandem
may
trigger
larg
number
neurologist
patient
reconsid
treatment
strategi
choic
initi
dmt
opt
less
effect
immunomodulatori
dmt
chang
need
consid
care
pandem
likelihood
short
live
would
unfair
patient
treat
epidem
disadvantag
long
term
regard
manag
ms
neurologist
spent
extraordinari
amount
time
effort
activ
ms
commun
advanc
principl
time
brain
treat
ms
proactiv
target
evid
diseas
activ
neda
recent
flip
pyramid
use
higher
efficaci
treatment
first
line
treatment
principl
evidencebas
thrown
context
potenti
yet
undefin
risk
patient
recommend
manag
italian
ms
patient
epidem
recommend
made
neurologist
infecti
diseas
specialist
whilst
evidencebas
data
present
given
lack
knowledg
data
diseas
cours
ms
patient
receiv
dmt
present
recommend
stop
differ
dmt
therefor
expos
ms
patient
risk
ms
exacerb
therefor
recommend
continu
current
dmt
specif
firstlin
dmt
betainterferon
glatiram
acet
teriflunomid
dimethyl
fumar
dmt
prescrib
usual
fingolimod
natalizumab
lymphodeplet
dmt
decis
dmt
base
individu
circumst
temporarili
delay
start
lymphodeplet
dmt
ocrelizumab
alemtuzumab
rituximab
cladribin
temporarili
delay
month
depend
dmt
redos
alemtuzumab
ocrelizumab
g
giovannoni
et
al
multipl
sclerosi
relat
disord
cladribin
decis
made
accord
individu
factor
diseas
sever
activ
dmt
recommend
delay
next
dose
even
beyond
month
lymphocyt
count
sever
decreas
time
next
dose
due
special
consider
patient
alreadi
receiv
first
dose
first
cycl
recommend
give
second
dose
ie
complet
first
cycl
extra
precaut
taken
patient
confirm
infect
withhold
first
secondlin
dmt
clinic
resolut
andor
approv
continu
treatment
infecti
diseas
specialist
note
given
potenti
antivir
activ
betainterferon
decis
continu
treatment
rest
treat
neurologist
symptom
potenti
infect
headach
anosmia
fever
dri
cough
asthenia
instruct
patient
attend
accid
emerg
servic
avoid
overcrowd
spread
viru
instruct
patient
call
local
emerg
number
describ
symptom
wait
instruct
evalu
temporari
withdraw
current
dmt
base
guidelin
provid
recommend
ms
patient
healthcar
profession
ms
centr
possibl
avoid
crowd
place
cinema
theatr
school
etc
high
risk
area
restrict
access
ms
centr
ms
patient
patient
immunosuppress
infus
therapi
use
protect
surgicalgrad
mask
recommend
travel
long
distanc
use
public
transport
absolut
necessari
recommend
use
protect
mask
hand
sanit
particularli
patient
fingolimod
alemtuzumab
ocrelizumab
cladribin
rituximab
possibl
work
home
good
person
hygien
alway
import
specif
recommend
wash
hand
frequent
ideal
alcoholbas
gel
alcohol
recommend
provid
guidelin
pleas
alway
refer
local
govern
advic
recommend
like
chang
depend
evolut
epidem
